A fast-acting nasal spray offers hope for hard-to-treat depression: study

Rates of depression are historically high.Roughly one in six American adults have depression, and 30% of them have tried multiple medications without getting the relief they need.While the first-line treatments are still therapy and traditional antidepressant medications, others are making a splash, offering a different approach to treating this disorder.People are treating their depression with everything from FDA-approved ketamine to gym supplement creatine and an EEG helmet paired with a video-game like training.Now, emerging evidence suggests the next big treatment might be a fast-acting drug that’s found on a desert toad.It’s called bufotenin — a psychedelic compound that belongs to the same family as serotonin.

It’s found in the skin, venom and eggs of a few toad species, especially the Colorado River toad, aka Sonoran Desert toad or Incilius alvarius.Drugmaker AtaiBeckley (which is owned by Eli Lilly) is seeing a single-dose nasal spray formula of the drug through clinical trials — now in phase 2b, with promising results.To be clear, no toads were harmed in the making of these drugs.AtaiBeckley synthesize the drug mebufotenin (5-MeO-DMT) in a lab.Researchers studied the drug with 193 adults aged 18 to 75, all of whom who had depression and had tried at least two antidepressants but didn’t feel enough relief.They split these participants into groups who got three different doses of the drug, and gave them psychological support before, during and after treatment.Both the low (8 mg) and high dose (12 mg) helped over 34% of participants.Those who took all three doses saw significant improvements to their depression, though the low dose (8 mg) saw the most — a 12 point reduction in depression scores on a 60-point scale.A quarter of those on the 8 mg dose saw a remission of their depression after a single treatment.

This doesn’t mean it was cured though, just that symptoms fell below a threshold for qualifying depression.Benefits appeared quick...